EHMT2 and chronic myelogenous leukemia, BCR-ABL1 positive: To test if inhibition of EHMT1 and EHMT2 enhances the anticancer effect of imatinib in CML, we investigated the cytotoxicity of imatinib in the presence or absence of BIX01294.